This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

MAJ Curt P. Samlaska, MC; CPT Diane K. Noyes, MC
USA Dermatology Service; USA Department of Medicine Tripler Army Medical Center Honolulu, HI 96859

Arch Dermatol. 1993;129(5):645-646.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Colony-stimulating factors are being used as supportive treatment for a multitude of systemic disorders, such as the human immunodeficiency virus, myelodysplasia, aplastic anemia, neutropenias, and chemotherapeuticinduced bone marrow toxicity.¹ All of these factors are produced by various cells within the skin, and their exact roles in cutaneous diseases are yet to be delineated. Administration of colony-stimulating factors is performed via intravenous or subcutaneous routes, and localized as well as generalized cutaneous reactions have been reported.^1,2 We observed localized cutaneous reactions associated with granulocyte colony-stimulating factor injections that were clinically and histologically similar to those observed for granulocyte-monocyte colony-stimulating factor. A pronounced eosinophil infltrate was observed despite the fact that, unlike granulocyte-monocyte colony-stimulating factor, granulocyte colony-stimulating factor does not promote eosinophil differentiation or activation.¹

Report of a Case.—

A 61-year-old Filipino woman presented with symptoms of chronic low back pain. Serum protein electrophoresis and bone . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?